Drugs / Intuvax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02686944 | Jun 2016 → May 2019 | gastrointestinal stromal tumor | Mendus | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2017-11-07 | Mendus | Results Immunicum AB (publ) Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting mendus.com ↗
The preclinical results show how ilixadencel induces complementary immunological processes that are needed in order to prime the immune system to recognize and destroy cancer cells. |
| 2016-11-14 | Mendus | Results Immunicum AB presented poster at SITC conference on INTUVAX HCC I/II clinical study – announces last patient included in study extension mendus.com ↗
today announced updated immunological and survival phase I/II data on hepatocellular carcinoma (HCC) patients treated with INTUVAX. |
| 2014-12-03 | Mendus | Results Immunicum reports continued promising survival data for INTUVAX-treated renal cancer patients mendus.com ↗
The median survival in the subgroup of five individuals who were initially classified as high-risk patients now stands at 19.8 months, compared with an expected median survival of nine months following current standard therapy. |
| 2014-12-03 | Mendus | Results Immunicum presents safety and survival data from a clinical phase I/II study with INTUVAX in patients with liver cancer mendus.com ↗
Immunicum AB (publ) today published an interim report on the safety and survival data from the ongoing phase I/II study with INTUVAX in patients with primary liver cancer. |
| 2014-06-02 | Mendus | Results Immunicum announces INTUVAX phase I/II data at ASCO 2014 mendus.com ↗
In addition to demonstrating a favorable safety profile, INTUVAX, as a single agent, has shown clear signs of tumor specific immune activation and encouraging survival data for patients with poor prognosis. |
| 2014-05-21 | Mendus | Results Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell … mendus.com ↗
The Company also announced that two patients, whose tumor metastases after INTUVAX-therapy progressed, received add-on therapy with tyrosine kinase inhibitors and subsequently showed remarkable regression of all remaining metastases. |
| 2014-05-15 | Mendus | Results Immunicum – INTUVAX abstract at ASCO 2014 mendus.com ↗
9 out of 11 evaluated patients exhibited an increase in circulating tumor-specific lymphocytes (IFN-G ELISPOT) after vaccination. |
| 2013-12-05 | Mendus | Results Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer mendus.com ↗
today announces positive survival data from a clinical phase I/II-study with the therapeutic cancer vaccine INTUVAX ® for the treatment of metastatic renal cancer. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intuvax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02686944 ↗ |
| Modality | Vaccine | “Therapeutic vaccine: allogeneic, proinflammatory dendritic cells” NCT02686944 ↗ |
| Route | Other | “suspension for intratumoral injection” NCT02686944 ↗ |